thiosulfates has been researched along with Sicca Syndrome in 2 studies
Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.
thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Non-uremic calciphylaxis is a rare, life-threatening condition characterized clinically by cutaneous necrosis and histologically by calcium deposition in small vessel walls." | 1.51 | Non-uremic calciphylaxis in a patient with multiple rheumatologic diseases. ( Cotter, D; Hinds, B; Kusari, A; Paravar, T, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goossens, J | 1 |
| Courbebaisse, M | 1 |
| Caudron, E | 1 |
| Bahans, C | 1 |
| Vacquerie, V | 1 |
| Melchior, J | 1 |
| Salle, PV | 1 |
| Moesch, C | 1 |
| Daudon, M | 1 |
| Frocht, V | 1 |
| Richette, P | 1 |
| Ea, HK | 1 |
| Guigonis, V | 1 |
| Kusari, A | 1 |
| Cotter, D | 1 |
| Hinds, B | 1 |
| Paravar, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Placebo-controlled Trial of the Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis.[NCT06155578] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2024-01-02 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for thiosulfates and Sicca Syndrome
| Article | Year |
|---|---|
Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: Two cases.
Topics: Adult; Calcinosis; Chelating Agents; Dermatomyositis; Female; Fibroblast Growth Factor-23; Humans; H | 2017 |
Non-uremic calciphylaxis in a patient with multiple rheumatologic diseases.
Topics: Calciphylaxis; Chelating Agents; Female; Humans; Kidney; Leg Ulcer; Lupus Erythematosus, Systemic; M | 2019 |